# A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

> **NCT05551117** · PHASE2 · TERMINATED · sponsor: **MacroGenics** · enrollment: 192 (actual)

## Conditions studied

- Castration-Resistant Prostatic Cancer
- Androgen-Independent Prostatic Cancer
- Androgen-Insensitive Prostatic Cancer
- Androgen-Resistant Prostatic Cancer
- Hormone Refractory Prostatic Cancer
- Anal Cancer
- Anal Neoplasm
- Carcinoma, Squamous Cell of Head and Neck
- Head and Neck Squamous Cell Carcinoma
- Laryngeal Squamous Cell Carcinoma
- Oral Squamous Cell Carcinoma
- Malignant Melanoma
- Melanoma
- Non-small Cell Lung Cancer
- Non-small Cell Carcinoma
- Small-cell Lung Cancer
- Small Cell Carcinoma

## Interventions

- **BIOLOGICAL:** vobramitamab duocarmazine 2.0 mg (Arm A)
- **BIOLOGICAL:** vobramitamab duocarmazine 2.7 mg (Arm B)
- **BIOLOGICAL:** vobramitamab duocarmazine
- **DRUG:** Abiraterone
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT05551117
- **Lead sponsor:** MacroGenics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-06-13
- **Primary completion:** 2024-07-04
- **Final completion:** 2025-01-23
- **Target enrollment:** 192 (ACTUAL)
- **Why stopped:** Business reasons
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05551117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05551117, "A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05551117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*